LOS ANGELES--(BUSINESS WIRE)--NantOmics, a leading next generation molecular diagnostic company and wholly owned subsidiary of NantWorks, today announced data supporting the use of comprehensive genomics and transcriptomic (panomics) analysis to guide and inform clinical treatment decisions to be presented at the American Association for Cancer Research (AACR) Precision Medicine Meeting in Salt Lake City on Monday, June 15, 2015. In addition, data will be presented demonstrating for the first time NantOmics’ novel bioinformatic predictive modeling, machine learning engine capable of predicting drug sensitivity or resistance based on genomic and transcriptomic data.
Help employers find you! Check out all the jobs and post your resume.
